G01N 2333/70575
Ngf/tnf-superfamily
Official title: NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
G01N2333/70575 (Ngf/tnf-superfamily) appears on 63 US grants and 145 published applications in this corpus.
Search patents in G01N- Granted patents
- 63
- Published applications
- 145
- Assignees
- 110
- Inventors
- 322
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 3 |
| 2004 | 0 | 2 |
| 2005 | 0 | 4 |
| 2006 | 0 | 5 |
| 2007 | 2 | 2 |
| 2008 | 2 | 1 |
| 2009 | 1 | 10 |
| 2010 | 5 | 5 |
| 2011 | 3 | 5 |
| 2012 | 4 | 7 |
| 2013 | 1 | 4 |
| 2014 | 1 | 4 |
| 2015 | 3 | 12 |
| 2016 | 2 | 11 |
| 2017 | 8 | 11 |
| 2018 | 0 | 2 |
| 2019 | 6 | 8 |
| 2020 | 9 | 10 |
| 2021 | 3 | 7 |
| 2022 | 3 | 6 |
| 2023 | 1 | 7 |
| 2024 | 4 | 8 |
| 2025 | 3 | 5 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Use of melanocortin-1 receptor agonist27 Jan 2026US 12,533,350 B2Tanabe Pharma Corporation
- Method for measuring systemic chronic inflammaging6 Jan 2026US 12,517,135 B2Edifice Health, Inc.
- Biomarker panels for on-treatment prediction of response to immuno-oncology drugs30 Sep 2025US 12,429,485 B2The Brigham and Women S Hospital, Inc.
- Signature of TL1A (TNFSF15) signaling pathway8 Apr 2025US 12,269,873 B2Cedars-Sinai Medical Center
- Signatures and determinants for diagnosing infections and methods of use thereof7 Jan 2025US 12,188,934 B2MeMed Diagnostics Ltd.
- Systems and Methods for the Prediction of Post-Operative Cognitive Decline Using Blood-Based Inflammatory Biomarkers6 Aug 2026US 2026/0229316 A1Assistance Publique-Hopitaux de Paris
- Clinical application of sbcma in cerebrospinal fluid in diagnosis and monitoring of central nervous system autoimmune diseases25 Jun 2026US 2026/0177550 A1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Biomarker panel for diagnosing pulmonary dysfunction25 Jun 2026US 2026/0177558 A1
- Methods for Diagnosing and Treating Vestibular Schwannoma21 May 2026US 2026/0140117 A1The Board of Trustees of the Leland Stanford Junior University
- Anti-drug antibody assays5 Mar 2026US 2026/0063643 A1Amgen Inc.
Most cited
By later US patents
- Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer110US 8,337,851 B2Novartis AG · 2012
- Methods for diagnosis and treatment of epithelial-derived cancers35US 7,261,892 B2Celltech R&D Limited · 2007
- Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins32US 7,385,032 B2Apotech Research and Development Ltd. · 2008
- Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor23US 7,838,639 B2Apoxis SA · 2010
- Signatures and determinants for diagnosing infections and methods of use thereof23US 9,726,668 B2MeMed Diagnostics Ltd. · 2017